BRCA1 and neoplasm: Although long-term outcomes for these patients, particularly the response to the treatments in case of tumor relapse, remain to be seen, the study of Byrski et al [1] has to be considered as the first long-awaited clinical argument for the preferential use of platinating agents in BRCA1 carriers.